Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mecapegfilgrastim + adebrelimab + docetaxel + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination therapy is a neoadjuvant regimen being investigated for the treatment of resectable locally advanced gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The regimen consists of **mecapegfilgrastim**, a long-acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) analog used to prevent chemotherapy-induced neutropenia; **adebrelimab**, a humanized IgG4 monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) to enhance anti-tumor immune responses; and the **FLOT** chemotherapy regimen, which includes **docetaxel**, **oxaliplatin**, **5-fluorouracil**, and **leucovorin**. This multi-modal approach combines cytotoxic chemotherapy with immune checkpoint inhibition and myeloid support to improve pathological complete response rates and surgical outcomes in patients with resectable gastric and gastroesophageal junction cancers.
- Other names
- Mecapegfilgrastim + Adebrelimab + FLOT
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)DNACD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on mecapegfilgrastim + adebrelimab + docetaxel + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mecapegfilgrastim + adebrelimab + docetaxel + oxaliplatin + 5-fluorouracil + leucovorin.